Vaxart, Inc.
VXRTNASDAQHealthcare● Active
$0.60
$-0.02(-3.44%)
Market Cap$144912237
P/E Ratio—
52W High$0.84
52W Low$0.26
Vaxart, Inc. (VXRT) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
VXRT · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 7, 2026EPS Actual
$0.02
Est. -$0.21 · +109.5%
Revenue
$0.04B
Est. $0.05B · -22.3%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 7, 2026
After Market Close
▲ Beat EPS▼ Miss Revenue🔥 7-Quarter EPS Beat Streak
VXRT reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.02
Rev. $0.33B
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.02
Rev. Est.$0.33B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 7, 2026 | -$0.21 | $0.02 | +109.5% | $0.04B | $0.05B | -22.3% |
| ▲ Q1 FY2026 | Mar 12, 2026 | -$0.08 | $0.24 | +400.0% | $0.10B | $0.04B | +190.0% |
| ▲ Q4 FY2025 | Nov 13, 2025 | -$0.07 | -$0.04 | +42.9% | $0.07B | $0.04B | +101.4% |
| ▲ Q3 FY2025 | Aug 13, 2025 | -$0.09 | -$0.07 | +22.2% | $0.04B | $0.00B | +1705.9% |
| — Q2 FY2025 | May 13, 2025 | -$0.07 | -$0.07 | +0.0% | $0.02B | $0.00B | +632.5% |
| ▲ Q1 FY2025 | Mar 20, 2025 | -$0.10 | -$0.05 | +50.0% | $0.02B | $0.02B | -26.9% |
| ▲ Q4 FY2024 | Nov 13, 2024 | -$0.10 | -$0.06 | +40.0% | $0.00B | $0.02B | -68.5% |
| ▼ Q3 FY2024 | Aug 8, 2024 | -$0.03 | -$0.09 | -237.5% | $0.01B | $0.00B | +6301.0% |
Q2 FY2026
May 7, 2026Beat
EPS Actual
$0.02
EPS Est.
-$0.21
EPS Surpr.
+109.5%
Revenue
$0.04B
Q1 FY2026
Mar 12, 2026Beat
EPS Actual
$0.24
EPS Est.
-$0.08
EPS Surpr.
+400.0%
Revenue
$0.10B
Q4 FY2025
Nov 13, 2025Beat
EPS Actual
-$0.04
EPS Est.
-$0.07
EPS Surpr.
+42.9%
Revenue
$0.07B
Q3 FY2025
Aug 13, 2025Beat
EPS Actual
-$0.07
EPS Est.
-$0.09
EPS Surpr.
+22.2%
Revenue
$0.04B
Q2 FY2025
May 13, 2025
EPS Actual
-$0.07
EPS Est.
-$0.07
EPS Surpr.
+0.0%
Revenue
$0.02B
Q1 FY2025
Mar 20, 2025Beat
EPS Actual
-$0.05
EPS Est.
-$0.10
EPS Surpr.
+50.0%
Revenue
$0.02B
Q4 FY2024
Nov 13, 2024Beat
EPS Actual
-$0.06
EPS Est.
-$0.10
EPS Surpr.
+40.0%
Revenue
$0.00B
Q3 FY2024
Aug 8, 2024Miss
EPS Actual
-$0.09
EPS Est.
-$0.03
EPS Surpr.
-237.5%
Revenue
$0.01B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2026 | $-0.03 | $-0.03 | $-0.03 | 1 |
| Q2 FY2026 | $-0.21 | $-0.21 | $-0.21 | 1 |
| Q1 FY2026 | $0.02 | $0.02 | $0.02 | 1 |
| Q4 FY2025 | $-0.07 | $-0.07 | $-0.07 | 1 |
| Q3 FY2025 | $-0.09 | $-0.07 | $-0.04 | 2 |
| Q2 FY2025 | $-0.11 | $-0.09 | $-0.07 | 2 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2026 | $0.1B | $0.1B | $0.1B | 1 |
| Q2 FY2026 | $0.1B | $0.1B | $0.1B | 1 |
| Q1 FY2026 | $0.1B | $0.1B | $0.1B | 1 |
| Q4 FY2025 | $-0.0B | $-0.0B | $-0.0B | 1 |
| Q3 FY2025 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2025 | $0.0B | $0.0B | $0.0B | 2 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 7, 2026 | +109.5% | $0.75 | $0.74 | -0.67% |
| ▲ Q1 FY2026 | Mar 12, 2026 | +400.0% | $0.77 | $0.74 | -3.90% |
| ▲ Q4 FY2025 | Nov 13, 2025 | +42.9% | $0.36 | $0.37 | +2.78% |
| ▲ Q3 FY2025 | Aug 13, 2025 | +22.2% | $0.38 | $0.37 | -2.63% |
| ▲ Q2 FY2025 | May 13, 2025 | +0.0% | $0.41 | $0.42 | +2.59% |
| ▲ Q1 FY2025 | Mar 20, 2025 | +50.0% | $0.58 | $0.57 | -2.79% |
| ▲ Q4 FY2024 | Nov 13, 2024 | +40.0% | $0.72 | $0.71 | -1.09% |
| ▼ Q3 FY2024 | Aug 8, 2024 | -237.5% | $0.60 | $0.63 | +5.74% |
Q2 FY2026-0.67%
Report Date
May 7, 2026
EPS Beat/Miss
+109.5%
Price Before
$0.75
Price After
$0.74
Q1 FY2026-3.90%
Report Date
Mar 12, 2026
EPS Beat/Miss
+400.0%
Price Before
$0.77
Price After
$0.74
Q4 FY2025+2.78%
Report Date
Nov 13, 2025
EPS Beat/Miss
+42.9%
Price Before
$0.36
Price After
$0.37
Q3 FY2025-2.63%
Report Date
Aug 13, 2025
EPS Beat/Miss
+22.2%
Price Before
$0.38
Price After
$0.37
Q2 FY2025+2.59%
Report Date
May 13, 2025
EPS Beat/Miss
+0.0%
Price Before
$0.41
Price After
$0.42
Q1 FY2025-2.79%
Report Date
Mar 20, 2025
EPS Beat/Miss
+50.0%
Price Before
$0.58
Price After
$0.57
Q4 FY2024-1.09%
Report Date
Nov 13, 2024
EPS Beat/Miss
+40.0%
Price Before
$0.72
Price After
$0.71
Q3 FY2024+5.74%
Report Date
Aug 8, 2024
EPS Beat/Miss
-237.5%
Price Before
$0.60
Price After
$0.63
Avg Beat Reaction-0.82%
Avg Miss Reaction+5.74%
Beat Rate7 / 8 quarters
Largest Move+5.74% (Q3 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: VXRT ends December
Vaxart, Inc. (VXRT) most recently reported earnings on May 7, 2026 for Q2 FY2026, posting EPS of $0.02 — beating the analyst consensus of $-0.21 by +109.5%. VXRT has beaten EPS estimates for 7 consecutive quarters. The next VXRT earnings date is expected around September 1, 2026.
Each quarter, investors track VXRT earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. VXRT revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
VXRT's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
VXRT earnings · 5 questionsVaxart, Inc.'s next earnings report is expected around September 1, 2026. VXRT typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; VXRT historically reports after market close (AMC).
VXRT earnings datewhen is VXRT earningsVXRT next earnings datewhen does VXRT report earningsVXRT earnings calendar
▸ Source: FMP · Vaxart, Inc. SEC filings · US GAAP · Vaxart, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026